CM
AGIO icon

Castleark Management’s Agios Pharmaceuticals AGIO Stock Holding History

Castleark Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-96,330
Closed -$8.11M – 371
2018
Q2 		$8.11M Buy
+96,330
New +$8.4M 0.25% 129

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Castleark Management's AGIO Position: Q3 2018 in Review

Castleark Management sold out of Agios Pharmaceuticals (AGIO) in Q3 2018, closing a stake of 96,330 shares — an estimated $8.11M sold.

Castleark Management first reported a position in AGIO in Q2 2018 and held it in 1 quarter. The position peaked at $8.11M in Q2 2018. 208 funds tracked by Wall St. Rank hold AGIO as of Q3 2018.

  • Castleark Management reported no remaining Agios Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Castleark Management sold 96,330 Agios Pharmaceuticals shares in Q3 2018, an estimated $8.11M.
  • Castleark Management first reported a position in Agios Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Castleark Management's Agios Pharmaceuticals position peaked at $8.11M in Q2 2018.
  • 208 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2018.

Based on Castleark Management's 13F filing for Q3 2018, filed 15 Nov 2018.